Lumida
/IBRX
⌘K
Immunitybio Inc

Immunitybio Inc

IBRX
$7.68USD+3.09%+0.23 today

MARKET CAP

8.0B

P/E (TTM)

FWD P/E

DAY RANGE

$7 – $8

52W RANGE

$2
$12

AI Summary

Stalk
Sell NowMedium

IBRX remains in a Stage 4 decline with confirmed support failure and a lower-high/lower-low regime. Medium-term bias is bearish, reinforced by Support Failure and Bearish Pivot Point patterns. Short-term conditions favor further downside as price rejects at declining 9EMA/20EMA and trades below the 50 SMA. The Momentum + EPS strategy calls for participating in the downtrend by selling into shallow rallies around the EMAs for disciplined entries. Long-term uptrend remains intact above the 200 DMA, anchoring structural polarity.

  • ANKTIVA Phase 3 trial efficacy drove an 8.92% jump post-ASCO presentation.
  • Analyst consensus ‘Strong Buy’ with $13 average target implies ~47.9% upside.
  • Q1 2026 net loss of $0.08/share missed estimates, underlining weak profitability.
Full analysis →
Insider Trades22 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Feb 22, 2026SellIBRXRegan J LauerChief Accounting Officer1,673$8.70$8.0B-38.21%+293.85%$14.6K-1.38%Trim
Feb 22, 2026SellIBRXDavid C. SachsChief Financial Officer20,682$8.70$8.0B-38.21%+293.85%$179.9K-5.72%Trim
Feb 22, 2026SellIBRXPatrick Soon-Shiong58,170$8.70$8.0B-38.21%+293.85%$506.1K-0.19%Trim
Feb 22, 2026SellIBRXRichard AdcockCEO & President77,560$8.70$8.0B-38.21%+293.85%$674.8K-9.81%Trim
Feb 10, 2026SellIBRXRegan J LauerChief Accounting Officer2,257$6.93$8.0B-38.21%+293.85%$15.6K-1.78%Trim
Feb 10, 2026SellIBRXDavid C. SachsChief Financial Officer42,643$6.93$8.0B-38.21%+293.85%$295.5K-8.75%Trim
Feb 10, 2026SellIBRXPatrick Soon-Shiong118,560$6.93$8.0B-38.21%+293.85%$821.6K-0.39%Trim
Feb 10, 2026SellIBRXRichard AdcockCEO & President140,048$6.93$8.0B-38.21%+293.85%$970.5K-11.93%Trim
Dec 31, 2025SellIBRXDavid C. SachsChief Financial Officer15,435$1.98$8.0B-38.21%+293.85%$30.6K-5.12%Trim
Dec 31, 2025SellIBRXRichard AdcockCEO & President17,510$1.98$8.0B-38.21%+293.85%$34.7K-4.16%Trim
Feb 22, 2025SellIBRXRegan J LauerChief Accounting Officer1,669$3.42$8.0B-38.21%+293.85%$5.7K-1.39%Trim
Feb 22, 2025SellIBRXDavid C. SachsChief Financial Officer15,860$3.42$8.0B-38.21%+293.85%$54.2K-4.91%Trim
Feb 22, 2025SellIBRXPatrick Soon-Shiong42,071$3.42$8.0B-38.21%+293.85%$143.9K-0.14%Trim
Feb 22, 2025SellIBRXRichard AdcockCEO & President78,167$3.42$8.0B-38.21%+293.85%$267.3K-10.89%Trim
Dec 31, 2024SellIBRXDavid C. SachsChief Financial Officer15,405$2.56$8.0B-38.21%+293.85%$39.4K-5.27%Trim
Dec 31, 2024SellIBRXRichard AdcockCEO & President17,475$2.56$8.0B-38.21%+293.85%$44.7K-4.80%Trim
Dec 15, 2024SellIBRXRegan J LauerChief Accounting Officer7,503$2.87$8.0B-38.21%+293.85%$21.5K-6.50%Trim
Feb 5, 2024SellIBRXRichard AdcockCEO & President43,165$4.04$8.0B-38.21%+293.85%$174.4K-15.08%Trim
Jan 31, 2024SellIBRXRegan J LauerChief Accounting Officer13,470$3.36$8.0B-38.21%+293.85%$45.3K-12.49%Trim
Jan 31, 2024SellIBRXDavid C. SachsChief Financial Officer26,835$3.36$8.0B-38.21%+293.85%$90.2K-12.62%Trim
Dec 31, 2023SellIBRXDavid C. SachsChief Financial Officer10,511$5.02$8.0B-38.21%+293.85%$52.8K-4.06%Trim
Dec 31, 2023SellIBRXRichard AdcockCEO & President17,096$5.02$8.0B-38.21%+293.85%$85.8K-5.02%Trim